Form 4 for JBIO Jade Biosciences, Inc.
Accepted 2024-03-20 00:00:00 ET · period of report 2024-03-18 · accession 0001415889-24-008771 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| DM | 2024-03-20 | 2024-03-18 | JBIO | Gillies Hunter | Chief MEDICAL Off | S - Sale+OE | $25.86 | -7,000 | 3,251 | -68% | -$181.0K |
| DM | 2024-03-20 | 2024-03-18 | JBIO | Gillies Hunter | Chief MEDICAL Off | M - OptEx | $1.91 | +7,000 | 7,251 | +2,789% | +$13.4K |
| DM | 2024-03-20 | 2024-03-18 | JBIO | Gillies Hunter | Chief MEDICAL Off | M - OptEx | $0.00 | -7,000 | 98.5K | -7% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2024-03-18 | S | D | 6,387 | $25.81 | 3,864 | D | — | — | (F2) The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $25.25 to $26.18, inclusive. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. |
| 2 | Common | Common Stock | 2024-03-18 | M | A | 3,000 | $2.14 | 10,251 | D | — | — | |
| 3 | Common | Common Stock | 2024-03-18 | M | A | 4,000 | $1.74 | 7,251 | D | — | — | |
| 4 | Common | Common Stock | 2024-03-18 | S | D | 613 | $26.40 | 3,251 | D | — | — | (F3) The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $26.25 to $26.75, inclusive. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. |
| 5 | Derivative | Stock Option (Right to Buy) | 2024-03-18 | M | D | 4,000 | $0.00 | 4,036 | D | $1.74 · — to 2030-09-03 | 4,000 Common Stock | (F4) A total of 16,097 shares subject to an employee stock option were granted on September 4, 2020, with 10% of this option vested on May 1, 2020, 22.5% vested on May 1 2021, and the remainder vesting in 36 substantially equal monthly installments thereafter. |
| 6 | Derivative | Stock Option (Right to Buy) | 2024-03-18 | M | D | 3,000 | $0.00 | 98,510 | D | $2.14 · — to 2031-04-01 | 3,000 Common Stock | (F5) A total of 109,640 shares subject to an employee stock option were granted on April 2, 2021, with the first installment vested on July 4, 2021, with shares vesting in 48 substantially equal monthly installments. |